Bloomberg Law
How Life Sciences Firms Can Reduce DOJ Enforcement Risks
May 6, 2021
The Anti-Kickback Statute has long been a driver of enforcement actions against the life sciences industry. In this article, Sidley lawyers explore areas that are most likely to draw enforcement scrutiny and how compliance programs can be updated to control risk going forward.
Contacts
Related Blogs
Capabilities
Suggested News & Insights
DAAG Brenna Jenny Warns Heightened FCA Enforcement Is “The New Normal,” Addresses Enforcement Priorities and PoliciesFebruary 20, 2026DAAG Jenny Reinforces Commitment to FCA Enforcement Premised on “Unlawful DEI”February 20, 2026DOJ Attorneys Underscore Heightened Focus on Trade Fraud During the Annual Qui Tam ConferenceFebruary 19, 2026OIG Releases Long-Awaited Medicare Advantage Compliance Program GuidanceFebruary 10, 2026FY 2025 FCA Settlements and Judgments Statistics Show Highest Recoveries EverJanuary 20, 2026First Circuit Clarifies Application of Medicare’s “Reasonable and Necessary” Standard in FCA Cases Against Clinical LabsDecember 8, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory